PHC
28.4.2022 12:07:18 CEST | Business Wire | Press release
PHC Holdings Corporation (hereafter PHC Group) (TOKYO:6523) today announced the appointment of Shoji Miyazaki as the company’s Chief Executive Officer. He succeeds John Marotta, who has stepped down as the company’s CEO and Representative Director and also from the Board of Directors effective April 28, 2022. Shoji Miyazaki remains a Representative Director on the company’s Board of Directors.
Shoji Miyazaki was previously PHC Group's Chief Operating Officer and former President of PHC Corporation and brings more than 30 years of experience at PHC Group and Panasonic. He joined Matsushita Kotobuki Electronics Co., Ltd. a predecessor of PHC Corporation in 1990, upon graduation. In 2001 he moved to Panasonic’s healthcare medical business unit, focusing on medical diagnostics, where he continued in numerous roles before being appointed Executive Vice President and COO of PHC Holdings Corporation in 2020. At the same time he also held Board positions at PHC Corporation and LSI Medience Corporation.
“I look forward to focusing on efficiency and integration, building on the work our team has delivered integrating our teams and portfolio since the acquisitions of Epredia and LSI Medience in 2019. Delivering value for patients, clinicians, business partners and shareholders remains PHC Group’s top priority,” commented Shoji Miyazaki.
In addition, effective July 1, 2022, Board Member Koichiro Sato will join PHC Group as Chief Operating Officer. On the same date, subject to approval of the proposal for election of directors at the General Meeting of Shareholders, he will become a Representative Director. His main responsibility will be overseeing company operations outside of Japan, where half PHC Group’s business and employees are located, including Ascensia, Epredia, and PHCbi NA and EU. Sato joins PHC Group from his current role as Chief Executive Officer in the Hong Kong Branch of MBK Healthcare Management Pte. Ltd. and he brings nearly 25 years of experience to PHC Group from his international career within Mitsui & Co. related companies. He entered the healthcare field in 2016 as a general manager in the Mitsui healthcare business division.
“We are pleased to welcome Shoji Miyazaki as PHC Group’s new CEO. He has a strong track record of leading global teams across diagnostics, life sciences, and diabetes, and is particularly well suited to driving the next leg of innovation from PHC Group. We continue to be committed to creating healthcare solutions that improve lives and strengthen our communities,” said Kyoko Deguchi, External Director.
“PHC Group looks forward to advancing our medium- and long-term plans to deliver global growth, innovation, efficiency, and performance, and to continue contributing to a healthier society. We thank John for his concentrated efforts on bringing the company to the IPO, streamlining and integrating the organization, and bringing consistency to PHC Group’s management systems and structures. We wish him all the best,” continued Ivan Tornos, External Director.
About PHC Holdings Corporation (PHC Group)
PHC Holdings Corporation (TOKYO:6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia, and LSI Medience Corporation. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2020 were JPY 306 billion with global distribution of products and services in more than 125 countries.
www.phchd.com/global
www.phchd.com/global/news/2022/0428
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005524/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 21:11:00 CEST | Press release
Authorizations add selection of ZYN ULTRA products to PMI U.S.’s growing portfolio of better alternatives for legal-age adults who smoke or use traditional oral tobacco products Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to furth
58% of Consumers Say They Don't Care Whether a Product is a National Brand or Private Label. They Just Buy What They Need21.8.2026 12:00:00 CEST | Press release
New NIQ & World Data Lab report reveals how consumer polarization is redefining value, accelerating private label adoption, and reshaping competition on the shelf As fast-moving consumer goods (FMCG) prices rose 26% globally between 2021 and 2025, consumers have become more deliberate about where they save and where they spend. NielsenIQ (NYSE: NIQ) has released new findings showing that private label is no longer viewed simply as a lower-cost substitute, but as a credible competitor across value, mainstream, and premium segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819950224/en/ Private label is no longer just a value play. The findings, published in NIQ’s latest report, A Tale of Two Consumers: The Polarized Mindsets Reshaping Global Consumption, created in collaboration with World Data Lab, show how consumer polarization is redefining value and reshaping competition on the shelf. The report also draws on ins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom